Revolutionizing mRNA Analysis: Enhancing Precision with Ultra-wide Pore Size Exclusion Chromatography Columns

Parrott Dressman*

Department of Biotechnology, Cairo University, Giza P.O. Box 12613, Egypt

Abstract

The advent of messenger RNA (mRNA) therapeutics has revolutionized the field of medicine, particularly in the treatment of genetic disorders and infectious diseases. However, the complexity of mRNA molecules necessitates precise and reliable analytical techniques to ensure their efficacy and safety. Traditional chromatographic methods for mRNA analysis often fall short in terms of resolution and throughput. This article introduces a novel approach to mRNA analysis using ultra-wide pore Size Exclusion Chromatography (SEC) columns, which promise to enhance the precision of mRNA characterization. By expanding the pore size range of SEC columns, this technique improves the separation and quantification of mRNA molecules based on their size and conformation. This article discusses the principles behind ultra-wide pore SEC, compares it with conventional methods, and highlights its advantages in terms of resolution, reproducibility, and sensitivity. The implementation of these advanced columns can significantly advance mRNA therapeutics development and quality control.

Keywords: mRNA analysis • Ultra-wide pore size exclusion chromatography • Precision enhancement • mRNA therapeutics • Analytical techniques • Separation science

Introduction

In recent years, mRNA therapeutics have gained immense popularity due to their potential to address a broad spectrum of diseases, including genetic disorders and viral infections. The efficacy and safety of these therapeutics hinge on the accurate characterization and quality control of mRNA molecules. Traditional analytical methods, such as conventional Size Exclusion Chromatography (SEC), have been instrumental but often encounter limitations in resolving complex mRNA structures. The development of ultra-wide pore size exclusion chromatography columns represents a significant advancement in this field, offering enhanced precision in mRNA analysis [1].

Size exclusion chromatography operates on the principle of molecular size-based separation. In conventional SEC, columns are designed with a specific pore size that allows molecules smaller than the pores to diffuse into the stationary phase, leading to separation based on size. However, traditional columns often struggle with high-resolution separation of larger mRNA molecules or those with complex conformations due to restricted pore sizes. Ultra-wide pore SEC columns address these challenges by incorporating a broader range of pore sizes. This expanded pore distribution accommodates a wider variety of molecular sizes and conformations, resulting in improved resolution of mRNA species. The increased pore size allows for more accurate separation of large mRNA molecules and their conformational variants, thus providing a more detailed profile of the mRNA sample [2].

Literature Review

Ultra-wide pore SEC columns provide superior resolution by accommodating a broader spectrum of molecular sizes. This capability is particularly beneficial for distinguishing between closely related mRNA species or detecting minor conformational changes. The improved resolution translates into better sensitivity for detecting and quantifying low-abundance

*Address for Correspondence: Parrott Dressman, Department of Biotechnology, Cairo University, Giza P.O. Box 12613, Egypt; E-mail: parrottessman@ses.eg

mRNA species. This is crucial for ensuring the consistency and efficacy of mRNA therapeutics. The uniformity of the ultra-wide pore structure contributes to consistent performance across different analytical runs. This reproducibility is vital for regulatory compliance and quality assurance in therapeutic development. The ability to analyze complex mRNA samples more efficiently accelerates the development process. High-throughput analysis becomes feasible, facilitating faster iteration and refinement of mRNA-based products. Ensuring the integrity and purity of mRNA therapeutics is crucial for safety and efficacy. Ultra-wide pore SEC columns provide detailed information on mRNA size distribution and impurities, supporting rigorous quality control processes [3].

Detailed characterization of mRNA molecules, including their size and structural variants, is essential for understanding their behavior and interaction with biological systems. This technique allows for comprehensive profiling of mRNA therapeutics. The enhanced precision and reproducibility of ultra-wide pore SEC columns meet stringent regulatory requirements, facilitating smoother approval processes for mRNA-based therapies. The introduction of ultra-wide pore size exclusion chromatography columns marks a significant advancement in the field of mRNA analysis. By enhancing resolution, sensitivity, and reproducibility, these columns address the limitations of conventional methods and offer a more precise approach to characterizing and quantifying mRNA molecules. This technological leap is poised to revolutionize mRNA therapeutics development, providing a robust foundation for future innovations in genetic medicine [4].

The integration of ultra-wide pore Size Exclusion Chromatography (SEC) columns into mRNA analysis is just the beginning. Combining ultra-wide pore SEC with other analytical methods such as mass spectrometry or High-Performance Liquid Chromatography (HPLC) could provide even more detailed insights into mRNA characteristics. Hybrid techniques could offer complementary data on mRNA sequence, modifications, and interactions, leading to a more comprehensive understanding of mRNA therapeutics. Tailoring ultra-wide pore SEC columns for specific types of mRNA, such as those with particular modifications or structures, could improve the resolution and accuracy of the analysis. Customizable pore sizes and column chemistries might address unique challenges associated with different mRNA therapeutics [5].

Discussion

Automating the ultra-wide pore SEC analysis process could streamline workflows, increase throughput, and reduce manual errors. Integrating these

columns with automated sample handling and data analysis systems could facilitate large-scale mRNA analyses and expedite therapeutic development. Developing advanced data analysis tools and software for interpreting the complex datasets generated by ultra-wide pore SEC could provide deeper insights into mRNA properties. Improved algorithms and machine learning approaches could assist in the precise quantification of mRNA species and their variants. As the technology matures, regulatory bodies may update guidelines and standards to incorporate ultra-wide pore SEC methods. Ongoing collaboration between researchers, industry professionals, and regulators will be essential to ensure that these new techniques meet regulatory requirements and gain widespread acceptance. Research into other advanced chromatographic techniques, such as ion-exchange chromatography or affinity chromatography with ultra-wide pore materials, could offer additional or complementary benefits for mRNA analysis. Exploring these alternatives could provide new opportunities for resolving complex mRNA samples [6].

Conclusion

Ultra-wide pore size exclusion chromatography columns represent a significant breakthrough in the analysis of mRNA therapeutics, offering enhanced resolution, sensitivity, and reproducibility. By overcoming the limitations of traditional SEC methods, these advanced columns provide a powerful tool for the precise characterization and quality control of mRNA molecules. The future of mRNA analysis will likely see further advancements through hybrid techniques, automation, and improved data analysis tools, driving continued innovation in the field of genetic medicine. As the technology evolves, researchers and industry professionals will need to stay abreast of developments and adapt to emerging techniques. The ongoing integration of ultra-wide pore SEC columns into mRNA analysis workflows holds great promise for advancing the understanding and development of mRNA-based therapies, ultimately contributing to better healthcare outcomes.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Duan, Qiongyu, Tianyu Hu, Qiuxia Zhu and Xueying Jin, et al. "How far are the new wave of mRNA drugs from us? mRNA product current perspective and future development." *Front Immunol* 13 (2022): 974433.

2. Damase, Tulsi Ram, Roman Sukhovershin, Christian Boada and Francesca Taraballi, et al. "The limitless future of RNA therapeutics." *Front Bioeng Biotechnol* 9 (2021): 628137.

3. Jackson, Nicholas AC, Kent E. Kester, Danilo Casimiro and Sanjay Gurunathan, et al. "The promise of mRNA vaccines: A biotech and industrial perspective." *NPJ Vaccines* 5 (2020): 11.

4. Currie, Jonathan, Jacob R. Dahlberg, Ester Lundberg and Linda Thunberg, et al. "Stability indicating ion-pair reversed-phase liquid chromatography method for modified mRNA." *J Pharm Biomed Anal* 245 (2024): 116144.

5. Goyon, Alexandre, Shijia Tang, Szabolcs Fekete and Daniel Nguyen, et al. "Separation of plasmid dna topological forms, messenger rna and lipid nanoparticle aggregates using an ultrawide pore size exclusion chromatography column." *Anal Chem* 95 (2023): 15017-15024.

6. De Vos, Jelle, Kris Morreel, Piotr Alvarez and Helena Vanluchene, et al. "Evaluation of size-exclusion chromatography, multi-angle light scattering detection and mass photometry for the characterization of mRNA." *J Chromatogr A* 1719 (2024): 464756.